Quick answers
- What is Matzim LA?
- Matzim LA is a brand name of Diltiazem, a prescription medicine. The FDA NDC Directory lists 5 Matzim LA products in 5 strengths and forms.
- Who makes Matzim LA?
- Actavis Labs Fl Inc holds the FDA application for Matzim LA (ANDA077686, approved March 15, 2010).
- Is there a generic or store brand of Matzim LA?
- Yes. The FDA NDC Directory lists 25 other products with the same active ingredients, strength and form as a Matzim LA product, 20 of them generic. Ask your pharmacist whether one is right for you.
- What do pharmacies pay for Matzim LA?
- CMS lists a National Average Drug Acquisition Cost (NADAC) for 5 Matzim LA strengths and forms (see the table below). That is what pharmacies pay to buy it, not what you pay: your price depends on your insurance and your pharmacy.
- Has Matzim LA been recalled?
- FDA enforcement reports list 2 recalls of Matzim LA products; the newest started July 21, 2022. A recall usually concerns specific lots, not every product.
What Matzim LA is
Each Matzim LA product as listed in the FDA NDC Directory, by active ingredient, strength and form, with its official label. “Same medicine, other names” counts the other products with exactly the same active ingredients, strength and form (generic versions, store brands and other brands); inactive ingredients can differ.
Diltiazem · prescription medicine
| Strength and form | Product names | Same medicine, other names | Label |
|---|---|---|---|
| diltiazem hydrochloride 180 mg tablet, extended release (oral) | Matzim LA | 5 products, 5 companies | — |
| diltiazem hydrochloride 240 mg tablet, extended release (oral) | Matzim LA | 5 products, 5 companies | — |
| diltiazem hydrochloride 300 mg tablet, extended release (oral) | Matzim LA | 5 products, 5 companies | — |
| diltiazem hydrochloride 360 mg tablet, extended release (oral) | Matzim LA | 5 products, 5 companies | — |
| diltiazem hydrochloride 420 mg tablet, extended release (oral) | Matzim LA | 5 products, 5 companies | — |
Its page lists every product and company, the FDA label’s uses and boxed warning, approvals, shortages and recalls: Diltiazem →
FDA approval
- ANDA: Abbreviated New Drug Application: how a generic version is approved.
| Application | Holder | First approved | Products |
|---|---|---|---|
| ANDA077686 | Actavis Labs Fl Inc | March 15, 2010 | 5 |
What pharmacies pay (NADAC)
The National Average Drug Acquisition Cost (NADAC) is the average price U.S. retail pharmacies paid to buy one unit of a medicine (one tablet, one mL or one gram), from a monthly survey of pharmacy invoices by the Centers for Medicare & Medicaid Services (CMS). State Medicaid programs use it to pay pharmacies.
This is not the price you pay. What you pay depends on your insurance (copay or coinsurance), your pharmacy and any discounts, and pharmacies also charge for filling a prescription. Ask your pharmacist or your health plan what your price will be.
| Strength and form | Generic or brand | Pharmacies pay |
|---|---|---|
| diltiazem hydrochloride 180 mg tablet, extended release | Generic: Matzim LA | $1.17 per tablet Generic of the same strength and form: $1.17 per tablet |
| diltiazem hydrochloride 240 mg tablet, extended release | Generic: Matzim LA | $1.05 per tablet Generic of the same strength and form: $1.05 per tablet |
| diltiazem hydrochloride 300 mg tablet, extended release | Generic: Matzim LA | $1.93 per tablet Generic of the same strength and form: $1.93 per tablet |
| diltiazem hydrochloride 360 mg tablet, extended release | Generic: Matzim LA | $1.75 per tablet Generic of the same strength and form: $1.75 per tablet |
| diltiazem hydrochloride 420 mg tablet, extended release | Generic: Matzim LA | $2.66 per tablet Generic of the same strength and form: $2.66 per tablet |
NADAC list of November 4, 2026; these prices took effect on October 21, 2026. Shown only where a package’s NDC code matches the NADAC list exactly, and only for that exact strength and form: nothing is averaged across strengths. Strengths and forms not listed here have no NADAC price.
Source: NADAC (National Average Drug Acquisition Cost) 2026, data.medicaid.gov (CMS) →
Companies that list Matzim LA
The company named on the package (holder, repackager or distributor), as listed in the FDA NDC Directory, with its number of Matzim LA products.
- Actavis Pharma, Inc.5 products
Recalls
From FDA enforcement reports, matched by the product’s NDC code or label. A recall usually covers specific lots: check the lot number on your package and ask your pharmacist. Do not stop a medicine on your own.
-
July 21, 2022 · Class II · Terminated · D-1302-2022
Failed Dissolution Specifications: below specification limits for dissolution.
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 180 mg, 30-count bottle, Rx Only, Manufactured by: Actavis Laboratories FL, Inc., Fort Lauderdale, FL 33314, USA; Distributed by: Actavis Pharma, Inc., Parsip — Teva Pharmaceuticals USA Inc
-
September 6, 2019 · Class III · Terminated · D-0131-2020
GMP Deviation: lot not intended for commercial distribution.
Matzim LA (Diltiazem Hydrochloride) Extended-Release Tablets, 240 mg, 30 count bottle, Rx only, Manufactured by: Actabis Laboratories FL, Inc., Fort Lauderdale, FL, Distributed by: Actavis Pharma, Inc., Parsippany, NJ ND — Teva Pharmaceuticals USA
Sources
- NDC Directory (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drugs@FDA (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug labeling (SPL, openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 30, 2026, retrieved October 31, 2026
- Drug recall enforcement reports (openFDA) — U.S. Food and Drug Administration (FDA), FDA data exported October 27, 2026, retrieved October 31, 2026
- NADAC (National Average Drug Acquisition Cost) 2026 — Centers for Medicare & Medicaid Services (CMS), data.medicaid.gov, list of November 4, 2026, retrieved November 7, 2026
Which names get a brand page: a name the NDC Directory lists for a medicine, held by one company (the FDA application holder, or the company named on most of its products), that is not just a description, and that is not the only product of its medicine.